The efficacy and safety of ipidacrine in patients with idiopathic neuropathy of the facial nerve (PELICAN study)

I. N. Samartsev, S. A. Zhivolupov, V. V. Ponomarev, M. N. Markova, K. R. Magomedov

Open source

DOI
10.14412/2074-2711-2022-1-60-68
Published
2022-02-26
Container
Neurology, Neuropsychiatry, Psychosomatics
Publisher
IMA Press, LLC
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.14412/2074-2711-2022-1-60-68,
  title = {The efficacy and safety of ipidacrine in patients with idiopathic neuropathy of the facial nerve (PELICAN study)},
  author = {I. N. Samartsev and S. A. Zhivolupov and V. V. Ponomarev and M. N. Markova and K. R. Magomedov},
  year = {2022},
  journal = {Neurology, Neuropsychiatry, Psychosomatics},
  doi = {10.14412/2074-2711-2022-1-60-68},
  url = {https://doi.org/10.14412/2074-2711-2022-1-60-68}
}

RIS

TY  - JOUR
TI  - The efficacy and safety of ipidacrine in patients with idiopathic neuropathy of the facial nerve (PELICAN study)
AU  - I. N. Samartsev
AU  - S. A. Zhivolupov
AU  - V. V. Ponomarev
AU  - M. N. Markova
AU  - K. R. Magomedov
PY  - 2022
JO  - Neurology, Neuropsychiatry, Psychosomatics
DO  - 10.14412/2074-2711-2022-1-60-68
UR  - https://doi.org/10.14412/2074-2711-2022-1-60-68
ER  - 

APA

Samartsev, I. N., Zhivolupov, S. A., Ponomarev, V. V., Markova, M. N., & Magomedov, K. R. (2022). The efficacy and safety of ipidacrine in patients with idiopathic neuropathy of the facial nerve (PELICAN study). Neurology, Neuropsychiatry, Psychosomatics. https://doi.org/10.14412/2074-2711-2022-1-60-68

Source records